◎记者 孙小程 西藏药业一度让不少同行艳羡——大单品新活素经久不衰，支撑其业绩常年保持稳定。 但硬币的另一面，显然是单一产品依赖度过高的风险，这是始终悬在西藏药业头顶的现实考题。 西藏药业生产线 西藏药业厂区 居安常思危，如何摆脱"单腿走路"的局面？ 近日，上海证券报记者走进西藏药业，探寻其在新时期的转型密码。西藏药业董事长陈达彬将其总结 为：内源性增长与外延式扩张并重。对内拓展新活素的市场覆盖率，深挖藏药资源护城河；对外通过投 资基因编辑企业，持续探索创新药前沿领域。"内外"兼修，让谋求可持续发展的西藏药业迈向更广阔的 增长空间。 守正于"内" 夯实发展根基 从雪域高原出发，西藏药业在二十余年的时间里，逐步构建起覆盖西藏、四川、上海及海外市场的产业 版图。 目前，西藏药业产品涵盖生物制药、藏药、中药和化学药领域，主要产品涉及心脑血管、肝胆、扭挫伤 及风湿、类风湿、感冒等，代表品种有新活素、依姆多、诺迪康、十味蒂达胶囊、雪山金罗汉止痛涂膜 剂、小儿双清颗粒等。 其中，新活素是西藏药业拥有自主研发的国家生物制品一类新药，是治疗急性心衰的基因工程药物。新 活素能快速改善心衰患者的心衰症状和体征，提高患者的生存质量 ...

证券日报网讯西藏药业（600211）11月17日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东总数45，448户。 ...

Market Overview - The biopharmaceutical sector increased by 0.3% on November 14, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down by 0.97%, while the Shenzhen Component Index closed at 13216.03, down by 1.93% [1] Stock Performance - Jindike (688670) closed at 28.03, up by 19.99% with a trading volume of 105,500 shares and a transaction value of 270 million [1] - Hualan Ting (301207) closed at 25.38, up by 7.22% with a trading volume of 336,800 shares [1] - Other notable performers include: - Saikai Pharmaceutical (300485) at 13.35, up by 4.54% [1] - Olin Bio (616889) at 24.81, up by 4.29% [1] - Wowo Bio (300357) at 33.65, up by 3.03% [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 59.84 million from institutional investors, while retail investors saw a net inflow of 23.85 million [2][3] - Key stocks with significant capital flow include: - Ganli Pharmaceutical (603087) with a net inflow of 62.98 million from institutional investors [3] - Jindike (688670) with a net inflow of 40.32 million from institutional investors [3] - Hualan Ting (301207) with a net inflow of 27.99 million from institutional investors [3]

Group 1 - The core viewpoint of the article is that Xizang Pharmaceutical (600211.SH) currently does not have a specific drug for treating influenza virus [1] - The company's product, Xiaor Shuangqing Granules, is a unique national Class III new drug and a Category B product under the national medical insurance [1] - Xiaor Shuangqing Granules is recommended in the "Clinical Application Guidelines for Traditional Chinese Medicine in Treating Acute Upper Respiratory Infections in Children - 2020" [1] Group 2 - The main function of Xiaor Shuangqing Granules is to clear heat and detoxify, addressing both exterior and interior conditions [1] - It is indicated for children with symptoms of exterior heat syndrome, including fever, runny nose, red throat, thirst, dry stools, red urine, red tongue, and yellow coating [1] - The product is used for acute upper respiratory infections presenting the aforementioned symptoms [1]

Core Viewpoint - The company currently does not have a specific drug for treating influenza virus, but it offers a product called Xiaoer Shuangqing Granules, which is a national Class III new drug and a Category B product under the national medical insurance system [1] Company Summary - Xiaoer Shuangqing Granules is exclusively produced and sold by the company [1] - The product is recommended in the "Clinical Application Guidelines for Traditional Chinese Medicine in Treating Acute Upper Respiratory Infections in Children - 2020" [1] - The main functions of the product include clearing heat and detoxifying, addressing both exterior and interior conditions [1] Indication Summary - The product is indicated for children with symptoms of exterior heat syndrome, including fever, runny nose, red throat, thirst, dry stools, red urine, red tongue, and yellow coating [1] - It is specifically used for acute upper respiratory infections presenting with the aforementioned symptoms [1]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].

Group 1 - The core point of the article highlights the recent performance of Tibet Pharmaceutical, which saw a 5.13% increase in stock price, reaching 47.12 CNY per share, with a trading volume of 238 million CNY and a turnover rate of 1.61%, resulting in a total market capitalization of 15.188 billion CNY [1] - Tibet Pharmaceutical, officially known as Tibet Nodi Kang Pharmaceutical Co., Ltd., is located in Lhasa Economic and Technological Development Zone and was established on July 14, 1999. The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1] Group 2 - From the perspective of fund holdings, data indicates that one fund under Chuangjin Hexin has a significant position in Tibet Pharmaceutical. The Chuangjin Hexin ESG Responsibility Investment Stock A (011149) held 22,500 shares in the third quarter, accounting for 2.49% of the fund's net value, making it the eighth largest holding. The estimated floating profit for today is approximately 51,700 CNY [2] - The Chuangjin Hexin ESG Responsibility Investment Stock A (011149) was established on December 30, 2020, with a latest scale of 21.7358 million CNY. Year-to-date returns stand at 23.35%, ranking 2503 out of 4216 in its category, while the one-year return is 13.54%, ranking 2934 out of 3913. Since inception, the fund has achieved a return of 18.47% [2] Group 3 - The fund managers of Chuangjin Hexin ESG Responsibility Investment Stock A (011149) are Gong Chao and Wang Xin. As of the report, Gong Chao has been in position for 4 years and 225 days, managing a total fund size of 168 million CNY, with the best return during his tenure being 15.27% and the worst being -24.28% [3] - Wang Xin has been in position for 4 years and 313 days, overseeing a total fund size of 428 million CNY, with the best return during his tenure being 25.06% and the worst being -16.16% [3]

Group 1: Market Performance - The biopharmaceutical sector increased by 3.42% compared to the previous trading day, with Sanofi leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Group 2: Stock Performance - Sanofi (688336) closed at 72.96, up 20.00% with a trading volume of 115,200 shares and a transaction value of 799 million [1] - Hualan Biological (301207) closed at 21.95, up 17.88% with a trading volume of 239,800 shares and a transaction value of 493 million [1] - Other notable stocks include Rongchang Bio (688331) up 11.80%, Jinke (688670) up 7.45%, and Kangchen Pharmaceutical (603590) up 7.38% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 590 million from institutional investors, while retail investors experienced a net outflow of 268 million [2] - Major stocks like Rongchang Bio and Sanofi had significant net inflows from institutional investors, with 145 million and 14.1 million respectively [2] - Retail investors showed a net outflow in several stocks, including Sanofi and Hualan Biological, indicating a shift in investor sentiment [2]

Group 1 - Tibet Pharmaceutical (600211.SH) reported its Q3 2025 results, with 15 institutional investors holding a total of 203 million shares, representing 62.88% of the company's total equity as of October 30, 2025 [1] - The top ten institutional investors collectively hold 62.72% of the shares, with a slight decrease of 0.01 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, namely Innovation Medicine, increased its holdings slightly, while five new public funds were disclosed this quarter [2] - A total of 72 public funds were not disclosed in the current period, including several major ETFs and mixed funds [2] - One social security fund, the Huaxia Fund Management Co., Ltd. - Social Security Fund 422 Portfolio, was not disclosed in the current period [2]